File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma

TitleAnti-inflammatory effects of high-dose montelukast in an animal model of acute asthma
Authors
Issue Date2003
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEA
Citation
Clinical and experimental allergy, 2003, v. 33 n. 3, p. 359-366 How to Cite?
AbstractBackground Asthmatic inflammation is mediated by a network of cytokines, chemokines and adhesion molecules. Corticosteroids are the only effective agents available to control asthmatic inflammation. We investigated the effect of high-dose montelukast (MK), a selective cysteinyl leukotriene receptor 1 antagonist, on mediators of airway inflammation. Objective The aim of this study was to determine the effect of a 3-day course of high-dose MK on mediators of airway inflammation induced by a single allergen challenge in sensitized mice. Methods Ovalbumin (OVA)-sensitized BALB/c mice were treated with 25 mg/kg of MK or saline intravenously for 3 days. On the third day, a single inhalation challenge with OVA was given. Cellular infiltration was assessed in the bronchoalveolar lavage (BAL) and in the lung. Expression of IL-4, IL-5, IL-13 and eotaxin in the BAL, and the lung was determined. Serum IL-5 and total IgE was measured. IL-5 and eotaxin mRNA expression in the lung was determined. Finally, eotaxin and VACM-1 expression in the lung was assessed by immunohistochemistry. Results MK reduced the number of eosinophils in the BAL by > 90%. There was also significant reduction in IL-5 in the BAL, lung and the serum, and IL-5 mRNA expression in the lung. IL-4 level in the lung and BAL, and IL-13 level in the lung also significantly decreased. Serum IgE level and lung VCAM-1 expression was also significantly lower in treated animals, but eotaxin protein and mRNA expression in the lung remained unchanged. Conclusion MK exerts its anti-inflammatory effect through the suppression of T helper type-2 (Th2) cytokines. The use of high-dose MK as an anti-inflammatory agent in acute asthma should be further explored.
Persistent Identifierhttp://hdl.handle.net/10722/222900
ISSN
2015 Impact Factor: 5.587
2015 SCImago Journal Rankings: 2.184

 

DC FieldValueLanguage
dc.contributor.authorWu, AY-
dc.contributor.authorChik, SC-
dc.contributor.authorChan, AW-
dc.contributor.authorLi, Z-
dc.contributor.authorTsang, KW-
dc.contributor.authorLi, W-
dc.date.accessioned2016-02-12T01:25:33Z-
dc.date.available2016-02-12T01:25:33Z-
dc.date.issued2003-
dc.identifier.citationClinical and experimental allergy, 2003, v. 33 n. 3, p. 359-366-
dc.identifier.issn0954-7894-
dc.identifier.urihttp://hdl.handle.net/10722/222900-
dc.description.abstractBackground Asthmatic inflammation is mediated by a network of cytokines, chemokines and adhesion molecules. Corticosteroids are the only effective agents available to control asthmatic inflammation. We investigated the effect of high-dose montelukast (MK), a selective cysteinyl leukotriene receptor 1 antagonist, on mediators of airway inflammation. Objective The aim of this study was to determine the effect of a 3-day course of high-dose MK on mediators of airway inflammation induced by a single allergen challenge in sensitized mice. Methods Ovalbumin (OVA)-sensitized BALB/c mice were treated with 25 mg/kg of MK or saline intravenously for 3 days. On the third day, a single inhalation challenge with OVA was given. Cellular infiltration was assessed in the bronchoalveolar lavage (BAL) and in the lung. Expression of IL-4, IL-5, IL-13 and eotaxin in the BAL, and the lung was determined. Serum IL-5 and total IgE was measured. IL-5 and eotaxin mRNA expression in the lung was determined. Finally, eotaxin and VACM-1 expression in the lung was assessed by immunohistochemistry. Results MK reduced the number of eosinophils in the BAL by > 90%. There was also significant reduction in IL-5 in the BAL, lung and the serum, and IL-5 mRNA expression in the lung. IL-4 level in the lung and BAL, and IL-13 level in the lung also significantly decreased. Serum IgE level and lung VCAM-1 expression was also significantly lower in treated animals, but eotaxin protein and mRNA expression in the lung remained unchanged. Conclusion MK exerts its anti-inflammatory effect through the suppression of T helper type-2 (Th2) cytokines. The use of high-dose MK as an anti-inflammatory agent in acute asthma should be further explored.-
dc.languageeng-
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEA-
dc.relation.ispartofClinical and experimental allergy-
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subject.meshAcetates - administration & dosage - pharmacokinetics-
dc.subject.meshAsthma - drug therapy-
dc.subject.meshChemokines, CC - genetics-
dc.subject.meshEosinophils-
dc.subject.meshLeukotriene Antagonists - administration & dosage - pharmacokinetics-
dc.titleAnti-inflammatory effects of high-dose montelukast in an animal model of acute asthma-
dc.typeArticle-
dc.identifier.emailWu, AY: adrianwu@hku.hk-
dc.identifier.emailChik, SC: chikscc@hkucc.hku.hk-
dc.identifier.emailLi, Z: zzli@hkuspace.hku.hk-
dc.identifier.emailTsang, KW: kwttsang@hkucc.hku.hk-
dc.identifier.doi10.1046/j.1365-2222.2003.01615.x-
dc.identifier.pmid12614451-
dc.identifier.hkuros100315-
dc.identifier.volume33-
dc.identifier.issue3-
dc.identifier.spage359-
dc.identifier.epage366-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats